CA Patent

CA2720547A1 — New combination for use in the treatment of inflammatory disorders

Assigned to Cardoz AB · Expires 2009-10-15 · 17y expired

What this patent protects

There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a compound that inhibits the formation and/or action of angiotensin II, or a pharmaceutically- acceptable salt or solvate thereof. Such combination …

USPTO Abstract

There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a compound that inhibits the formation and/or action of angiotensin II, or a pharmaceutically- acceptable salt or solvate thereof. Such combination products fmd particular utility in atherosclerosis and related conditions.

Drugs covered by this patent

Patent Metadata

Patent number: CA2720547A1
Jurisdiction: CA
Classification: —
Expires: 2009-10-15
Drug substance claim: No
Drug product claim: No
Assignee: Cardoz AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.